Consumer ads for Rx drugs should be stopped until regulations are finalized, Public Citizen tells FDA.
DIRECT-TO-CONSUMER AD BAN SHOULD BE REINSTATED UNTIL POLICY IS OUT, HRG asserts in comments to FDA on DTC prescription drug ads. "It is critical that DTC prescription drug advertising be stopped until consumer protective regulations can be proposed and finalized," Public Citizen's Health Research Group writes in an Aug. 12 letter to FDA. "The only reliable way to ensure that consumers will not be misled is to require that all DTC advertising be approved by the FDA prior to its distribution."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth